NCI Cancer Bulletin: A Trusted Source for Cancer Research News
NCI Cancer Bulletin: A Trusted Source for Cancer Research News
November 9, 2004 • Volume 1 / Number 43 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe

NCI Cancer Bulletin Archive

Page Options

  • Print This Page
  • Print This Document
  • View Entire Document
  • Email This Document
  • View/Print PDF

The information and links on this page are no longer being updated and are provided for reference purposes only.

International Flags

Special Announcement
Hawk Takes Over NCI's Office of Centers, Training, and Resources

Dr. Ernest Hawk, chief of NCI's Gastrointestinal and Other Cancers Research Group in the Division of Cancer Prevention, will assume a new role as the director of NCI's Office of Centers, Training and Resources (OCTR), effective November 14. Dr. Hawk, who first came to NCI in 1993 as a cancer prevention fellow, replaces acting director Dr. Linda Weiss in this role, which she assumed upon retirement of OCTR's previous director last January. Dr. Hawk brings extensive peer review and grants oversight experience to his new appointment, where he will oversee OCTR's four branches and be responsible for scientific, fiscal, and administrative management. Dr. Weiss will resume her previous position as chief of the Cancer Centers Branch and Dr. Jaye Viner will serve as acting chief of the Gastrointestinal and Other Cancers Research Group.

Bridging the International Divide
NCI is advancing the cancer fight globally through a series of partnerships with foreign cancer counterparts, extending from Asia to the Middle East to Europe. These bilateral agreements involve sharing research information and researchers across international borders.

NCI's longest such relationship is the 30-year-old U.S.-Japan Cooperative Cancer Research Program. Under this agreement, the two nations have sponsored more than 250 seminars and collaborated on more than 500 researcher exchanges.

The current focus of the exchange program is to provide junior scientists from both countries with mentoring, training, and research experience while working on research projects of mutual interest to the host laboratories.

NCI also is working with the National Translational Cancer Research Network of the United Kingdom to establish translational research fellowships in cancer, to train future generations of translational cancer researchers and build working relationships between these researchers on both sides of the Atlantic. Under this initiative, a shared Fellow would receive 3 years of support for working on a translational research project of mutual interest to the U.S. and the UK, splitting that fellowship period equally in both countries. It is expected that two fellowships will be awarded in 2005 and two fellowships every year thereafter.

Additionally, NCI is expanding a bilateral cancer relationship with Italy's Istituto Superiore di Sanità (ISS) beyond the area of pharmacogenomics. Under the existing partnership, several joint research projects have been identified and collaborative research is ongoing. NCI and ISS also cosponsored a workshop on cancer vaccines in Rome last April.

Russian Flag Reaching Out to Russia
NCI and its Russian counterparts in the cancer fight moved closer to a formal alliance last June after NCI Director Dr. Andrew C. von Eschenbach and NCI's OIA Director Dr. Joe Harford joined Health and Human Services (HHS) Secretary Tommy G. Thompson on a delegation trip to meet with Russian health officials on their soil.

A significant component of that trip involved the visit to the N.N. Blokhin National Cancer Research Center in Moscow, the largest cancer treatment center in Russia. While in Moscow, Secretary Thompson and members of the HHS delegation also met with the leaders of the American-Russian Cancer Alliance (ARCA), which was started nearly 3 years ago, with participants from the University of Maryland Greenebaum Cancer Center in Baltimore; the Fox Chase Cancer Center in Philadelphia; the Blokhin Center; and the Kurchatov Institute, the premier Russian nuclear research center.

ARCA's goal is to develop a partnership among American and Russian scientists engaged in cancer prevention and therapy. Its mission is to pool the intellectual and scientific resources of both countries, which will lead to positive results in cancer control more quickly and efficiently than if done in each country independently. Among the ARCA projects is a groundbreaking project funded by the U.S. to use Russia's expertise and nuclear facilities to produce research radioisotopes for diagnostic and therapeutic applications in oncology.

Another outcome from the HHS delegation was the creation of a joint cancer communications activity that will allow personnel from both countries' institutions to interact. In addition to NCI, the activity will involve communications personnel from the Centers for Disease Control and Prevention, the two academic institutions currently involved with ARCA, and several U.S. nongovernmental entities. Plans are also on the table to organize a Russia-U.S. activity centered on cancer prevention.

Costa Rican Flag NCI's International Research Contributions
NCI, in addition to conducting a national research program, also supports cancer-related research around the world. For instance, recruitment for a phase III trial is underway in Guanacaste, Costa Rica to evaluate the efficacy of a vaccine to protect women against two oncogenic strains of human papillomavirus (HPV). NCI researchers, in collaboration with the Foundation for the Costa Rican Institute for Research and Training in Nutrition and Health (Fundación INCIENSA) and the Costa Rican Ministry of Health, plan to test a virus-like particle (VLP) vaccine originally developed at NCI. Costa Rica was chosen for the phase III trial due to its high rate of cervical cancer.

Led by Dr. Allan Hildesheim of NCI's Division of Cancer Epidemiology and Genetics (DCEG) and Dr. Rolando Herrero of Fundación INCIENSA, the 8-year study will randomize 12,000 to 15,000 women aged 18 to 25 years to receive either the VLP or a control vaccine. Enrollees will receive three vaccinations over a period of 6 months and will participate in follow-up screening for several more years. Preclinical studies in the United States and elsewhere have repeatedly suggested the potential usefulness of VLP HPV vaccines. Other trials have also suggested that this type of vaccine shows adequate short-term protection from persistent HPV infections in women.

Other studies in which DCEG has been involved include research collaborations with China, Japan, Africa, Russia, Australia, and Europe, some dating back as far as the early 1970s. For example, NCI and the Shanghai Cancer Institute of China have been collaborating on numerous projects, including a prospective study to evaluate causes of cancer among women in China. In Africa, NCI has teamed up with the Ugandan Virus Research Institute to study AIDS-related cancers such as Kaposi's sarcoma. DCEG has also played an important role in a partnership between investigators in Australia, Europe, and the U.S. to map novel melanoma susceptibility genes and better understand the risk factors for melanoma.  

Scientists from Around the World Train at NCI - One of the most prominent examples of NCI's commitment to train foreign cancer researchers is found in the cadre of scientists working in NCI intramural laboratories. In fiscal year 2004, more than 1,000 researchers from 73 countries (represented by red dots in this map) contributed to projects in NCI's Center for Cancer Research while preparing themselves for careers in cancer research in their native countries. In addition, many current leaders in cancer research around the globe spent time at NCI earlier in their careers.For more information about the NIH Visiting Program, see Top 10 Countries Represented: Japan (156) People's Republic of China (139) Republic of Korea (119) India (105) Russia (53) Canada (48) Italy (47) Germany (45) France (37) Spain (26)